Somaxon (SOMX), P&G (PG) to Evaluate Doxepin OTC Potential Through March 31st, 2012
Tweet
Share
E-mailGet Alerts SOMX Hot Sheet
Join SI Premium – FREE
In a Form 8-K Friday morning, Somaxon Pharma (Nasdaq: SOMX) disclosed on November 23rd, the company and The Proctor & Gamble Distributing Company announced an amendment to a prior agreement which allows for the company's to work together to evaluate the potential to develop and commercialize an over-the-counter pharmaceutical product containing doxepin as the sole active pharmaceutical ingredient until March 31st, 2012.
During the evaluation period, Somaxon agreed not to negotiate rights in and to an OTC Product with any third party.
During the evaluation period, Somaxon agreed not to negotiate rights in and to an OTC Product with any third party.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sky Quarry names Heidi Bowman as CFO
- UDynamics files for Nasdaq IPO of 5.6 million shares at $5-$7 per share
- Magna Holdings makes unsolicited bid for 31% of Yatra Online
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
